This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Labor shortages and other headwinds have battered hospices during 2022, including large companies. This has been a longstanding problem since the start of the pandemic, but average length of stay among the publicly traded firms tumbled at a faster rate in Q3 2022 (3%) than they did in the third quarter of 2021 (2%).
In 2022, the hospice community laid the groundwork for a transformational 2023. During late 2021 and 2022, the U.S. Centers for Medicare & Medicaid Services (CMS) developed new approaches for enforcing hospice regulations that will become effective on Jan. 3–6 Big Provider, Payer Hospice Deals.
Though hospice deal volume dipped in 2022 compared to previous years, five particular transactions could paint a larger picture of where investors see value in the space. These interesting, unusual or groundbreaking deals could signal what’s to come in 2023 and help shape the hospice market’s long-term future. s (NYSE: HUM) $2.8
Addus HomeCare Corp. NASDAQ: ADUS) has reached an agreement to purchase the home health, hospice and private duty operator Tennessee Quality Care for $106 million. About 70% of its business is home health, including private duty, with hospice care comprising 30%. The company’s net service revenue reached $251.6
Having a window into priorities such as career development and work-life balance is a significant retention factor for the Dallas-based home health and hospicecompany, Marion indicated. This is down from 54% of respondents in 2023’s survey and 68% of 2022 respondents. 2024 Hospice News Outlook Survey and Report.
While a range of publicly traded companies and private equity firms have nevertheless snapped up hospices in record numbers, the skyrocketing valuations have led some to wait it out for a price drop. NYSE: CHEM), and the nation’s largest hospicecompany by market share, according to LexisNexis.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content